TARA — Protara Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $276.37m
- $120.82m
Annual cashflow statement for Protara Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -47.3 | -66 | -40.4 | -44.6 | -57.4 |
| Depreciation | |||||
| Non-Cash Items | 13.1 | 38.7 | 6.66 | 4.45 | 3.65 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.516 | 0.539 | -4.14 | 4.01 | -2.94 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -34.5 | -26.5 | -37.6 | -35.8 | -56.4 |
| Capital Expenditures | -0.596 | -0.12 | -0.045 | -0.063 | -0.094 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -97.6 | 15.1 | 53.2 | 19.2 | -139 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -98.2 | 14.9 | 53.1 | 19.2 | -139 |
| Financing Cash Flow Items | — | — | — | — | -0.614 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.228 | -0.09 | -0.091 | 140 | 82.7 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -133 | -11.6 | 15.5 | 123 | -113 |